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INTRODUCTION
FDG-PET/CT can demonstrate tumor metabolism
and morphology in a single session. Thus it has
an important role in tumor imaging. PET/CT is also
useful to differentiate malignant from benign lesions,
define staging, detect recurrence at an early stage,
and monitor therapeutic effects.
Malignant pleural mesothelioma (MPM), which
arises from the pleura and is the mostly associated
with asbestos exposure, is a common neoplasm of
mesothelial cells (1). MPM usually develops 20-40
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years after exposure to asbestos. It can occur from
direct occupational exposure as well as from indi-
rect exposure. Its incidence has been increasing.
Histologically, MPM is classified into three types :
epithelial (60%), biphasic (30%), and sarcomatous
(10%) types (2). The epithelial type is the most com-
mon and has the best prognosis. MPM is a very ag-
gressive disease and invades to the chest wall, me-
diastinum, and diaphragm. MPM also metastasizes
to hilar and mediastinal lymph nodes. Distant metas-
tases occur in approximately 10-20% of patients. Im-
aging examinations are necessary for management
of MPM patients.
We report our experience of FDG-PET/CT in
MPM patients.
PATIENTS AND METHODS
A Summary of the patients is shown in Table 1.
We performed 13 FDG-PET/CT studies in 9 pa-
tients with MPM (8 males, 1 female, aged 51 to 84
years, 9 at the initial diagnosis, 4 follow up studies).
Five patients had a history of asbestos exposure
(56%). Three of the 9 patients had extrapleural pneu-
monectomy and chemotherapy/radiation therapy.
Four patients had only chemotherapy, and 2 patients
refused any treatment. All patients fasted for at least
4 hours before the PET/CT scan and blood glucose
levels were checked as being150 mg/dl at the
time of injection. 18F-FDG (3.7 MBq/kg of body
weight) was administered intravenously using an
automatic injection system. After FDG injection, pa-
tients rested on bed for one hour. Talking, walking,
or other physical activities were prohibited to reduce
unnecessary muscle uptake. One hour after injec-
tion, images were obtained using PET/CT machine
equipped 16-slice multi-detector row CT.
We reviewed FDG-PET/CT findings of primary
tumors, recurrent tumors, lymph nodes, metastases.
RESULTS
All primary and recurrent tumors were FDG posi-
tive. The uptake patterns of the 9 patients at initial
diagnosis were ; diffuse+multi-nodular uptake pat-
tern in 5, diffuse irregular thickened uptake pattern
in 2, some focal thickened pattern in one, and a
slight diffuse uptake pattern in one. Two of the 3
patients diagnosed as N0 by PET and operated on
had negative lymph nodes confirmed pathologically.
Table 1 A summary of the patients.
Initial diagnosis
age gender asbestosexposure
uptake
pattern Histlogy cTNM pTNM SUVmax
other
findings Treatment outcome
pt.1 61 m + DMN epithelioid susp. T2N0M0 not confirmed 5.4 chemo dead
pt.2 60 m - DMN epithelioid T3N2M1 not confirmed 8.1 paraaortic LN+ no (patient refused) dead
pt.3 59 m + DMN epithelioid T3N0M0 T3N0M0 13.2 EPP+chemo dead
pt.4 56 m + DMN biphasic T3N2M0 T3N2M0 23.3 chemo dead
pt.5 55 m + DMN biphasic T3N0M0 T3N0M0 3.7 colon polyp EPP+RT alive
pt.6 84 m + DI uncertain T3N0M0 not confirmed 6.2 no (patient refused) dead
pt.7 77 f - DI biphasic T4N2M0 not confirmed 11.8 chemo dead
pt.8 59 m - FT epithelioid T2N0M1 T2N0M1 3.1 lung mets chemo alive
pt.9 51 m - SLD epithelioid T1N0M0 T3N2M0 1.7 EPP+chemo+RT dead
Follow up
Treatment time after1st PET
uptake
pattern SUVmax
pt.1 chemo 3 mo DMN local recurrence, subclavicular LN+ 7.4
pt.3 EPP+chemo 5 mo MN local recurrence 13.2
pt.5 EPP+RT 1 mo DMN progressed disease 5.2
pt.9 EPP+chemo+RT 9 mo DMN local recurrence 6.2
DMN : diffuse multi -nodular, DI : diffuse irregular, FT : focal thickening, SLD : slight diffuse, MN : multi -nodular
EPP : extrapleural pneumonectomy, RT : radiation therapy
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The other patient diagnosed as N0 by PET, had a
one month time lag between PET/CT examination
and surgery, was confirmed as N2 by extrapleural
pneumonectomy. In 3 patients, hilar or mediastinal
lymph nodes were difficult to distinguish from ir-
regular pleural thickening. One patient had a FDG
positive lymph node in the ipsilateral supraclavicu-
lar region confirmed as metastasis (N3). One patient
had a FDG positive lymph node in the para-aortic
region. Lung metastasis was seen in one patient
(M1). In another patient, two focal nodular uptakes
in the colon were detected and confirmed as colon
polyps (Group 3-4).
At follow up studies (1-9 months after first PET/
CT), local recurrence and disease progression was
demonstrated as FDG positive. Three of 4 patients
having follow up scans showed diffuse+multi-nodu-
lar uptake while the other showed multi-nodular up-
take.
CASE PRESENTATION
Patient 7 (Fig. 1) : A 77 year-old female with no
history of direct asbestos exposure was admitted
with left pleural effusion and pleural thickening.
FDG-PET/CT clearly demonstrated intense diffuse
thickened FDG uptake. It was difficult to differentiate
a pleural lesion from hilar lymph node metastasis.
No FDG positive lymph node was seen in the con-
tralateral hilar and supraclavicular region. There was
no evidence of distant metastasis.
Patient 5 (Fig. 2) : A 55 year-old male with a his-
tory of asbestos exposure was admitted with dysp-
nea. FDG-PET/CT demonstrated diffuse and multi-
nodular uptake in the right pleura. No hilar or me-
diastinal lymph node abnormalities or distant metas-
tasis were seen (N0 on FDG-PET/CT). He under-
went an extrapleural pneumonectomy and pT3N0
was confirmed. Two focal uptakes were demon-
strated in the pelvis corresponding to the rectum.
Following our recommendation of colon fiberscopic
examination, these uptakes confirmed as colon pol-
yps (group 3-4).
Patient 9 (Fig. 3) : A 51 year-old male with no his-
tory of asbestos exposure was admitted with a pro-
longed right pleural effusion. FDG-PET/CT demon-
strated a slight diffuse uptake along the pleura.
There was no evidence of lymph node metastasis or
distant metastasis. His disease progressed very rap-
idly and extrapleural pneumonectomy one month
after PET/CT examination confirmed pT3N2. After
10 months, follow up PET/CT study clearly demon-
strated recurrent lesions as FDG positive.
a b
c
Fig. 1 Seventy-seven year-old female. a) MIP image of FDG-
PET. b) Axial view of PET/CT. c) Coronal view of PET/CT.
FDG-PET/CT clearly demonstrated intense diffuse FDG uptake
in thickened pleura. It is difficult to differentiate pleural lesion from
hilar lymph node metastasis. No FDG positive lymph node was
seen in the contralateral hilar and supraclavicular region. There
was no evidence of distant metastasis.
a b
c
d
Fig. 2 Fifty - five year-old male. a) MIP image of FDG-PET.
b) Axial view of PET. c) Axial view of CT. d) Axial view of PET/
CT. FDG-PET/CT demonstrated diffuse and multi -nodular up-
take in the right pleura. No hilar or mediastinal lymph node ab-
normalities and no distant metastasis were seen. A focal uptake
is demonstrated in the pelvis corresponding to the rectum (ar-
row), confirmed as a polyp (group 4).
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DISCUSSION
MPM is a very rapidly progressing disease and
easily invades to adjacent structures such as the
chest wall, mediastinum, and diaphragm. Lymph
node metastases and/or distant metastases can oc-
cur to organs such as lungs, liver, adrenal glands,
and brain. Prognosis is related to the extent of the
primary tumor and metastases. Stage I and II pa-
tients can be candidates for surgery, while stage III
and IV patients are considered unresectable. Sur-
gery (extrapleural pnemonectomy, pleurectomy/
decortication), radiation therapy, chemotherapy or
their combination is often performed but the over-
all survival is low (3-5). Imaging techniques such
as CT, MRI and PET/CT have essential pre- and
post-treatment roles in detecting tumors and evalu-
ating the extension of MPM (6). CT is the most
widely used modality, but tends to underestimate
tumor invasion and lymph node metastases (7, 8).
MRI is superior for evaluating tumor involvement
(9). Perfusion CT or perfusion MRI can demonstrate
tumor microvasculature, while perfusion MRI is
used to assess the effects of treatment (10). There
are also reports concerning the utility of FDG-PET
or FDG-PET/CT (6, 11, 12). PET may predict sur-
vival of MPM patients, and can detect extrathoracic
metastases ; thus assisting treatment planning. By
using the uptake changes of FDG, PET can monitor
the response to chemotherapy (13). However, the
utility of PET is limited for T and N staging with sen-
sitivity reported to be 19% and 11%, respectively
(12). It is sometimes difficult to evaluate MPM inva-
sion to adjacent structures such as chest wall or me-
diastinum. FDG accumulates not only in the tumor
but also in an inflammatory lesion of asbestos related
pleuritis. In one of our patient (Patient 9), a slight
unilateral uptake was seen in the slightly thickened
pleura. This patient had a pneumonectomy one
month after the PET/CT examination. pT3N2 was
confirmed at surgery, and PET/CT demonstrated a
recurrence 9 months after surgery. This showed the
aggressive nature of MPM and the usefulness of
PET/CT to evaluate recurrent MPM. For N staging,
it is sometimes difficult to distinguish hilar or me-
diastinal lymph node metastases from a pleural tu-
mor or irregular pleural thickening. False-negative
lymph nodes and false-positive FDG uptake in me-
diastinal nodes is frequently seen. In this study, hi-
lar or mediastinal lymph node enlargement could
not be differentiated from irregular pleural thicken-
ing in 3 of the 9 patients. On the other hand, FDG-
positive lymph nodes in the supraclavicular and para-
aortic regions were clearly demonstrated. PET/CT
was useful to detect lung metastasis and unsus-
pected disease (colon polyps). We were also able to
use intense FDG uptake as a landmark for biop-
sies. In follow up studies, recurrent tumors clearly
showed as FDG positive.
We classified uptake pattern in 4 types. The rela-
tionship between the uptake pattern and histopa-
thological type, and patient outcome could not been
clarified in our small number of patients ; however,
we need to know the uptake pattern and that MPM
in the early stage can show a slight laterality of pleu-
ral uptake. FDG-PET/CT is useful for detecting dis-
tant metastasis and for evaluating activity in supracla-
vicular or abdominal lymph nodes. It is also useful
for identifying unsuspected diseases. It is important
for clinicians to know the advantages and limitations
of various imaging modalities for management of
MPM patients.
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